Loading company…
NeoChord, Inc. makes the DS1000 device for minimally invasive mitral valve repair, based in St. Louis Park, US.
NeoChord, Inc. is a medical technology company focused on mitral valve repair, with its NeoChord Artificial Chordae Delivery System (DS1000) used in a minimally invasive, echo-guided procedure for mitral valve regurgitation. Founded in 2007 and based in St. Louis Park, US, the company raised USD 3.80 mn in its April 2019 Series D round from Treo Ventures, part of a larger USD 32 mn round, at a valuation of USD 42.86 mn. David Chung and Todd Berg serve as CEOs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in